Skip to main content

Peer Review reports

From: Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial

Original Submission
8 Feb 2018 Submitted Original manuscript
30 Apr 2018 Reviewed Reviewer Report - Harald Herrmann
24 May 2018 Reviewed Reviewer Report - Hsin-An Hou
27 Jun 2018 Author responded Author comments - Kyriakos Papadopoulos
Resubmission - Version 2
27 Jun 2018 Submitted Manuscript version 2
20 Jul 2018 Author responded Author comments - Kyriakos Papadopoulos
Resubmission - Version 3
20 Jul 2018 Submitted Manuscript version 3
Publishing
24 Jul 2018 Editorially accepted
6 Aug 2018 Article published 10.1186/s12885-018-4692-z

You can find further information about peer review here.

Back to article page